Clinical trials: sponsored by Merck Sharp & Dohme LLC
Benign Prostatic Hyperplasia (BPH) Requiring Surgical Resection
Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration
The purpose of this study is to demonstrate the prostatic diffusion in significant concentration of ertapenem achieved after a pre-operative single administration.
- Trial name
- ERTAPRO (NCT02041767)
- Testing
- Ertapenem
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma
Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma
The goal of this clinical trial is to evaluate the efficacy and safety of Pembrolizumab in combination with Olaparib in participants with relapsed/refractory Peripheral T-cell Lymphoma (PTCL).
- Trial name
- POLAR (NCT06160843)
- Testing
- Pembrolizumab IV infusion Q3W, with daily oral Olaparib.
- Where
- Singapore
- Volunteers
- 24 people
- Sponsor
- National Cancer Centre, Singapore
Advanced Urothelial Carcinoma, Advanced Non Small Cell Lung Cancer
A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer
To confirm a recommended Phase 2 dose (RP2D) of FF-10832 (Gemcitabine Liposome Injection) given intravenously Day 1 of a 21-day cycle, in combination with 200 mg pembrolizumab given intravenously Day 1 of the same 21-day cycle…
- Trial name
- NCT05318573
- Testing
- Pembrolizumab, FF-10832
- Where
- 23 sites in United States
- Volunteers
- 120 people
- Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
Healthy
A Clinical Study of How Coffee and Tea Affect Enlicitide in Healthy Volunteers (MK-0616-040)
The goal of this study is to learn what happens to enlicitide in a person's body over time when enlicitide is taken at the same time as coffee or tea.
- Trial name
- NCT07044479
- Testing
- Enlicitide
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Prevention, Pre-exposure Prophylaxis
Stick2PrEP Cisgender Women and Trans Individuals
Taking a daily anti-HIV pill can protect people from HIV infection. This is called preexposure prophylaxis [PrEP]. Many cisgender women and trans individuals do not know this medication is available; others struggle to take the…
- Trial name
- S2P:CWTI (NCT05165745)
- Testing
- Individualized Feedback
- Where
- United States
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- Columbia University
Colorectal Cancer, BRAF V600E Mutation Positive
Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer
This is a pilot trial which aims to assess the concept of anti-BRAF neoadjuvant treatment (encorafenib) in combination with cetuximab in patients with colon cancer or rT3/T4 supra-peritoneal upper rectal cancer based on a…
- Trial name
- NEORAF (NCT05706779)
- Testing
- Encorafenib Oral Capsule + Cetuximab
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Carcinoma, Non-Small-Cell Lung, Melanoma
Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)
This study has been designed to evaluate the safety of pembrolizumab in participants in India with unresectable or metastatic melanoma and participants with non-small cell lung cancer (NSCLC) who are either untreated (programmed…
- Trial name
- NCT03715205
- Testing
- Pembrolizumab
- Where
- 8 sites in India
- Volunteers
- 150 people
- Sponsor
- Merck Sharp & Dohme LLC
Ulcerative Colitis
A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of MK-6194 in participants with active UC.
- Trial name
- NCT04924114
- Testing
- MK-6194
- Where
- 17 sites in United States, Georgia and 6 more
- Volunteers
- 57 people
- Sponsor
- Merck Sharp & Dohme LLC
Bladder Cancer
Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)
This study is designed to assess the efficacy and safety of induction therapy with MK-3475 and ASG-22CE and radiation therapy with MK-3475 in patients with cT2-4aN0M0 muscle invasive bladder cancer who are unfit for or refuse…
- Trial name
- NCT05879653
- Testing
- MK-3475, ASG-22CE, maximal TURBT
- Where
- 4 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Kyoto University Hospital
Metastatic Melanoma, Unresectable Melanoma
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
Phase 3, multicenter, international, open-label, randomized, 2-arm trial investigating the safety and efficacy of IO102-IO103 in combination with pembrolizumab as first-line treatment for patients with previously untreated…
- Trial name
- NCT05155254
- Testing
- IO102-IO103, Pembrolizumab
- Where
- 112 sites in United States, Australia and 14 more
- Volunteers
- 407 people
- Sponsor
- IO Biotech
Sarcoma, Liposarcoma
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
This research study is studying a combination of drugs (chemotherapy + Immunotherapy) as a possible treatment for liposarcoma, leiomyosarcoma, or undifferentiated pleomorphic sarcoma that has spread and has not responded to…
- Conditions
- Sarcoma, Liposarcoma, Leiomyosarcoma, Undifferentiated Pleomorphic Sarcoma
- Trial name
- NCT03899805
- Testing
- Eribulin, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- Dana-Farber Cancer Institute
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)
This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian…
- Conditions
- Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- ARTISTRY-7 (NCT05092360)
- Testing
- Nemvaleukin and Pembrolizumab Combination, Pembrolizumab, Nemvaleukin
- Where
- 117 sites in United States, Australia and 12 more
- Volunteers
- 456 people
- Sponsor
- Mural Oncology, Inc
Gastroesophageal Junction (GEJ) Adenocarcinoma
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma
This study is to evaluate the effectiveness of treatment for esophagogastric junction carcinoma, total neoadjuvant therapy (TNT) including pembrolizumab and FLOT is conducted, aiming to choose between surgery or organ…
- Trial name
- NCT07018570
- Testing
- Pembrolizumab, Docetaxel, Oxaliplatin
- Where
- Japan
- Volunteers
- 26 people
- Sponsor
- National Cancer Center Hospital East
Healthy
A Study of the Effect of Multiple Doses of Diltiazem on the Plasma Levels of MK-6916 in Healthy Participants (MK-6916-005)
The goal of the study is to learn what happens to levels of MK-6916 in a healthy person's body over time. Researchers will compare what happens to MK-6916 in the body when it is given with or without another medicine called…
- Trial name
- NCT06818968
- Testing
- MK-6916, Diltiazem
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma
A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)
The purpose of the study is to assess the efficacy, safety, and tolerability when combining pembrolizumab with epacadostat or placebo in participants with unresectable or metastatic melanoma
- Trial name
- NCT02752074
- Testing
- pembrolizumab + epacadostat
- Where
- 129 sites in United States, Australia and 21 more
- Volunteers
- 706 people
- Sponsor
- Incyte Corporation
Acute Myeloid Leukemia
MRD-guided Treatment in NPM1mut AML Patients
Evaluation the safety and efficacy of Pembrolizumab (PEM) when administered in combination with standard Azacitidine (AZA) in nucleophosmin (NPM1) mutated AML patients with molecular relapse defined by the presence of measurable…
- Trial name
- PEMAZA (NCT03769532)
- Testing
- Pembrolizumab, Azacitidine
- Where
- 10 sites in Germany
- Volunteers
- 26 people
- Sponsor
- Technische Universität Dresden
Healthy
A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005)
The goal of the study is to learn what happens to levels of MK-7602 in a healthy person's body over time. Researchers will compare what happens to MK-7602 in the body when it is given with or without another medicine called…
- Trial name
- NCT06797674
- Testing
- MK-7602, Efavirenz
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer
Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)
The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to pembrolizumab plus placebo as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC)…
- Trial name
- NCT03322540
- Testing
- Pembrolizumab, Epacadostat
- Where
- 101 sites in United States, Australia and 16 more
- Volunteers
- 154 people
- Sponsor
- Incyte Corporation
UC (Urothelial Cancer)
Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab + epacadostat vs pembrolizumab + placebo in participants with cisplatin-ineligible urothelial carcinoma.
- Trial name
- NCT03361865
- Testing
- Pembrolizumab, Epacadostat
- Where
- 143 sites in United States, Australia and 16 more
- Volunteers
- 93 people
- Sponsor
- Incyte Corporation
UC (Urothelial Cancer)
Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab + epacadostat vs pembrolizumab + placebo as a treatment for recurrent or progressive metastatic urothelial carcinoma in patients who have failed a…
- Trial name
- NCT03374488
- Testing
- Pembrolizumab, Epacadostat
- Where
- 135 sites in United States, Australia and 16 more
- Volunteers
- 84 people
- Sponsor
- Incyte Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.